MASLD treatment : a shift in the paradigm is imminent

• Author(s): Machado, Mariana
• Date: 2023
• Persistent ID: http://hdl.handle.net/10451/63037
• Origin: Repositório da Universidade de Lisboa
• Subject(s): MASLD; Liver disease-targeted drugs; Obesity; Treatment; Weight loss
• Document Type: Journal article
• Language: English
• Contributor(s): Repositório Científico de Acesso Aberto da ULisboa

Description

MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents.